How common is lipedema?

Estimates suggest around 11% of women, but this figure comes from specialist-clinic studies and likely overstates true population prevalence, which is unknown. The condition is widely underdiagnosed, so the true number is uncertain.

How long does it typically take to get a lipedema diagnosis?

Research documents an average diagnostic delay of approximately 17 years. This reflects low awareness among general practitioners and the tendency to attribute lipedema symptoms to obesity or lifestyle.

What percentage of women have lipedema?

The most widely cited figure is approximately 11%, but this comes from referral and clinic populations, not general-population surveys. True prevalence is unknown. The obsolete "1 in 72,000" figure is not supported by current evidence.

Is lipedema more common than people think?

Almost certainly yes. A 17-year average diagnostic delay means many affected people have not yet been counted. Awareness is increasing, and more cases are being recognized as clinicians learn to identify the condition.

Lipedema statistics and facts (2026)

Researched against current medical guidelines
Every claim sourced & linked to a named authority
Independent — we don’t sell surgery
Not a substitute for your doctor.

Sources · Read more

Written by the Lipedema Help editorial team Edited & fact-checked by the Lipedema Help editorial team

Last updated June 22, 2026

Lipedema is often cited as affecting up to ~11% of women, but that figure comes from specialist-clinic studies and likely overstates the true population rate, which is uncertain. What's well documented: long diagnostic delays (~17 years), high family history rates, and a heavy quality-of-life toll.

Last updated June 22, 2026 1 min read

On this page

Key lipedema statistics at a glance
Why does it take ~17 years to be diagnosed?
What do studies show about symptoms and quality of life?
Why are the statistics uncertain?

Key lipedema statistics at a glance

~11%

Estimated prevalence in women (clinic-data estimate; true rate uncertain)

~17 years

Average diagnostic delay from symptom onset to diagnosis

<1%

Estimated proportion of cases in men

15–64%

Range of patients with positive family history, across studies

94%

Of patients in one US survey reported pain as a primary symptom

707

Patients in Aday et al. 2024 US survey — largest recent US dataset

Prevalence caveat

The "~11% of women" figure cited in many places comes from specialist-referral or clinic-based studies — not validated population-level surveys. True general-population prevalence is unknown and likely well below 11%, but far above the obsolete "1 in 72,000" estimate. Interpret prevalence claims with appropriate skepticism.

Why does it take ~17 years to be diagnosed?

The ~17-year average diagnostic delay is one of the most striking findings in lipedema research¹. Contributing factors include:

Low awareness among primary care physicians
Symptoms commonly attributed to obesity or lack of exercise
No single diagnostic test — diagnosis requires a knowledgeable clinician
Patients frequently dismissed or told to "just lose weight"
Limited medical school curriculum coverage of the condition

What do studies show about symptoms and quality of life?

The Aday et al. 2024 survey of 707 US patients with lipedema¹ provides the most comprehensive recent US data:

Pain is reported as a symptom by the vast majority of patients
Easy bruising is among the most consistently reported features
Depression, anxiety, and disordered eating are among the most common co-occurring conditions
Functional limitations — reduced mobility and inability to perform daily activities — are widespread in moderate-to-advanced stages

Why are the statistics uncertain?

Lipedema is underdiagnosed — meaning that any statistic based on known cases underestimates the true number. The ~17-year delay means millions of people with the condition haven't yet been counted. Population-level epidemiological studies with validated criteria are largely missing.

The diagnostic criteria themselves have evolved. The 2021 US Standard of Care² and the 2026 Delphi Consensus³ have refined the definition, which affects how retrospective data should be interpreted.

Sources

Aday et al., Vascular Medicine 2024 — 707-patient US survey pmc.ncbi.nlm.nih.gov
Herbst KL et al., US Standard of Care — Phlebology 2021 journals.sagepub.com
Delphi Consensus — Nature Communications 2026 nature.com

Pinterest Facebook WhatsApp X Reddit